- The Wall Street Journal•10 hours ago
GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.
- Benzinga•2 days ago
Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: ...
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||34.94 x 2100|
|Ask||34.95 x 800|
|Day's Range||34.86 - 35.04|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||30.95|
|Avg Vol (3m)||22,033,106|
|Dividend & Yield||1.20 (3.45%)|